» Articles » PMID: 38993887

Type I Interferons Augment Regulatory T Cell Polarization in Concert with Ancillary Cytokine Signals

Overview
Specialty General Surgery
Date 2024 Jul 12
PMID 38993887
Authors
Affiliations
Soon will be listed here.
Abstract

In the transplant community, research efforts exploring endogenous alternatives to inducing tolerogenic allo-specific immune responses are much needed. In this regard, CD4 FoxP3 regulatory T cells (T) are appealing candidates due to their intrinsic natural immunosuppressive qualities. To date, various homeostatic factors that dictate T survival and fitness have been elucidated, particularly the non-redundant roles of antigenic CD3/T-cell-receptor, co-stimulatory CD28, and cytokine interleukin (IL-)2 dependent signaling. Many of the additional biological signals that affect T remain to be elucidated, however, especially in the transplant context. Previously, we demonstrated an unexpected link between type I interferons (IFNs) and T in models of multiple myeloma (MM)-where MM plasmacytes escaped immunological surveillance by enhancing type I IFN signaling and precipitating upregulated T responses that could be overturned with specific knockdown of type I IFN signaling. Here, we elaborated on these findings by assessing the role of type I IFN signaling (IFN-α and -β) on T homeostasis within an alloimmune context. Specifically, we studied the induction of T from naïve CD4 T cells. Using and models of murine skin allotransplantation, we found that type I IFN indeed spatiotemporally enhanced the polarization of naïve CD4 T cells into FoxP3 T. Notably, however, this effect was not independent of, and rather co-dependent on, ancillary cytokine signals including IL-2. These findings provide evidence for the relevance of type I IFN pathway in modulating FoxP3 T responses and, by extension, stipulate an additional means of facilitating T fitness type I IFNs.

Citing Articles

Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival.

Sausen D, Poirier M, Spiers L, Smith E Front Immunol. 2024; 14:1289313.

PMID: 38179040 PMC: 10764432. DOI: 10.3389/fimmu.2023.1289313.

References
1.
Piehler J, Thomas C, Garcia K, Schreiber G . Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev. 2012; 250(1):317-34. PMC: 3986811. DOI: 10.1111/imr.12001. View

2.
Steinman R, Hawiger D, Nussenzweig M . Tolerogenic dendritic cells. Annu Rev Immunol. 2003; 21:685-711. DOI: 10.1146/annurev.immunol.21.120601.141040. View

3.
Cohan S, Hendin B, Reder A, Smoot K, Avila R, Mendoza J . Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021; 35(7):743-767. PMC: 8258741. DOI: 10.1007/s40263-021-00822-z. View

4.
van Boxel-Dezaire A, Rani M, Stark G . Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006; 25(3):361-72. DOI: 10.1016/j.immuni.2006.08.014. View

5.
Fantini M, Dominitzki S, Rizzo A, Neurath M, Becker C . In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc. 2007; 2(7):1789-94. DOI: 10.1038/nprot.2007.258. View